Welcome to our dedicated page for Miromatrix Medical news (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical stock.
Miromatrix Medical Inc. (MIRO) is revolutionizing organ transplantation through its proprietary bioengineering technology. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in addressing the global organ shortage crisis.
Access timely updates including quarterly financial results, clinical trial milestones, leadership developments, and strategic partnerships. Our curated collection features verified information about MIRO's perfusion platform advancements and industry recognition, such as their recent American Transplant Congress honors.
Key content categories include regulatory updates, research publications, executive team announcements, and manufacturing scale-up progress. Bookmark this page to stay informed about MIRO's pioneering work in creating transplant-ready human organs through their decellularization technology.
Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences innovator, is presenting at the 2023 Cell & Gene Meeting on the Mediterranean in Barcelona, Spain, from April 12 to 14. CEO Jeff Ross, Ph.D., will moderate a panel on April 13 at 2:00 PM CET, discussing the challenges and opportunities in innovation. This will be followed by a company presentation at 3:30 PM CET, both of which will be live-streamed. Miromatrix focuses on bioengineering transplantable organs, addressing the human organ shortage. The event, expected to attract over 500 attendees, is pivotal for cell and gene therapy discussions including market access, regulatory frameworks, and commercialization.
The conference establishes a networking platform among industry leaders, with more than 60 presentations scheduled. For more details, visit miromatrix.com.
CareDx and Miromatrix Medical have entered an exclusive partnership to enhance the development of fully transplantable human bioengineered organs. CareDx will provide innovative testing solutions and donor-derived cell-free DNA (dd-cfDNA) testing services to assess acute allograft rejection in Miromatrix's clinical studies. This collaboration aims to address the critical organ shortage, with over 100,000 people in the U.S. awaiting transplants and 17 dying daily due to this shortage. Both companies express optimism about their joint efforts in pioneering transplant innovations.
Miromatrix Medical Inc. (NASDAQ: MIRO) reported its fourth quarter and full year 2022 financial results, emphasizing its focus on the miroliverELAP™ therapy for acute liver failure patients. The company aims to achieve FDA clearance for a Phase 1 clinical trial and has secured a collaborative agreement with Baxter International. Financially, Miromatrix ended 2022 with $25.2 million in cash, down from $52.8 million in 2021, and reported an operating loss of $30.364 million for the year. Licensing revenue increased to $953,470 in 2022 from $33,066 in 2021, reflecting collections from Reprise Biomedical. A conference call is scheduled for March 31, 2023.
Miromatrix Medical Inc. (NASDAQ: MIRO), a leader in bioengineering fully transplantable organs, will announce its fourth quarter and full year 2022 financial results on March 31, 2023, after market close. Management will conduct a conference call at 3:30 PM CT to discuss these results. Interested parties can join the call via domestic and international numbers or through a live webcast on the company's investor relations webpage. Miromatrix focuses on utilizing its proprietary perfusion technology to address the shortage of human organs, specifically developing applications for human livers and kidneys.
